Biohaven announces investment up to $600 million by oberland capital

Up to $600 million in non-dilutive capital in exchange for capped milestone and royalty payments on future troriluzole product net sales $250 million to be funded at closing $150 million available at the company's option upon the achievement of regulatory milestones related to troriluzole up to $200 million at the mutual agreement of the parties for permitted strategic acquisitions and related costs and expenses new haven, conn. , april 28, 2025 /prnewswire/ -- biohaven ltd.
BHVN Ratings Summary
BHVN Quant Ranking